Intravitreal ranibizumab in choroidal neovascularisation due to multifocal choroiditis and panuveitis syndrome

We report the use of intravitreal ranibizumab as initial and only treatment in a case of peripapillary choroidal neovascularisation (CNV) in a patient with multifocal choroiditis and panuveitis (MCP) syndrome. A 54-year-old woman presented with sudden reduced vision in the right eye of 2 weeks durat...

Full description

Saved in:
Bibliographic Details
Published in:BMJ case reports 2013-07, Vol.2013, p.bcr2013009572
Main Authors: Dardabounis, Doukas, Alvanos, Efstratios, Gatzioufas, Zisis, Panos, Georgios D
Format: Article
Language:English
Subjects:
Angiogenesis Inhibitors - administration & dosage
Antibodies, Monoclonal, Humanized - administration & dosage
Cataracts
Choroidal Neovascularization - drug therapy
Choroiditis - complications
Diabetic retinopathy
Europe (West)
Female
Fluorescein Angiography
Growth factors
Humans
Inflammation
Inflammatory diseases
Intravitreal Injections
Macular degeneration
Middle Aged
Multifocal Choroiditis
Novel Treatment (New Drug/Intervention
Established Drug/Procedure in New Situation)
Panuveitis - complications
Patients
Permeability
Ranibizumab
Syndrome
Vision Disorders - etiology
White
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report the use of intravitreal ranibizumab as initial and only treatment in a case of peripapillary choroidal neovascularisation (CNV) in a patient with multifocal choroiditis and panuveitis (MCP) syndrome. A 54-year-old woman presented with sudden reduced vision in the right eye of 2 weeks duration. A full ophthalmological examination was performed including biomicroscopy, fluorescein angiography and optical coherence tomography. A peripapillary choroidal neovascular membrane with subretinal haemorrhage extending to the fovea was revealed due to MCP syndrome. Three intravitreal injections of ranibizumab were performed with monthly intervals. There was clearance of the subretinal haemorrhage and reduction of the leakage after the first injection. The visual acuity improved to 20/20 in 3 months and remained stable at 2-year follow-up without angiographical leakage. Intravitreal injections of ranibizumab could be tried in cases of CNV due to MCP syndrome with very good response.
ISSN:1757-790X
1757-790X
DOI:10.1136/bcr-2013-009572